SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biocryst Pharmaceuticals Inc (BCRX)
An SI Board Since January 2004
Posts SubjectMarks Bans Symbol
269 15 0 BCRX
Emcee:  SemiBull Type:  Unmoderated
Introduction Market Data Compact
BioCryst Pharmaceuticals, Inc. is focused on designing, optimizing and developing novel small molecule pharmaceuticals that block key enzymes essential for cancer, cardiovascular diseases and viral infections. BCRX's most advanced drug candidate, BCX-1777, is an investigational purine nucleoside phosphorylase inhibitor for the treatment of T-cell mediated disorders. BCRX's TF/FVIIa inhibitor project has emerged as its highest priority discovery program. BCRX has designed and synthesized a group of compounds that are potent and selective inhibitors of the Tissue Factor/Factor VIIa and further optimization is ongoing. BCRX has also identified one compound, BCX-3607, for clinical development. The goal is to advance BCX-3607 into clinical development for treatment of unstable angina during 2003, while seeking a partner to develop and potentially commercialize this class of inhibitors.

Any thoughts on this biotech in Birmingham, Alabama?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
269BCRX caps a stunning 2 week run with a 20 % move up after pricing a secondary. Hsjemmeri-8/1/2013
268Would have made for a great short! Have to think the BCRX shareholders may vote rkrw-10/31/2012
267BCRX’s HCV nuke was based on obsolete and discredited technology. (It was a nuclDewDiligence_on_SI-10/31/2012
266So much for their rationale for merging with Presidio. rkrw-10/30/2012
265>> Bugg's great HCV molecule is vapor. But the backups are incredible,scaram(o)uche-10/30/2012
264a couple small director buys here..mopgcw-2/12/2010
263CC Transcript SeekingAlpah: BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2009 Earnimopgcw-2/5/2010
262from seekingalpah: BioCryst: Israel Orders 150 Doses of H1N1 Antiviral Peramivirmopgcw-12/21/2009
261from SeekingAlp[ha: BioCryst's Korean Partner Receives Emergency Use Authorimopgcw-12/9/2009
260BioCryst Receives First Peramivir Order From U.S. Government * Press Releasnicewatch-11/5/2009
259Emergency Use Authorization Granted For BioCryst's Peramivir October 23, 200nicewatch-10/24/2009
258got out too early it appears. Alas.mopgcw-7/24/2009
257I am completely out now too. licking my wounds over the long haul on this bad bmopgcw-7/21/2009
256I was far too greedy. I'd hoped to re-enter in the low $2 range and completIan@SI-7/17/2009
255What fun. Guess the Baker Boys sold a bit too early (me as well).... What to dmopgcw-7/17/2009
254Peramvir (IV!) demonstrated non-inferiority to Tamiflu in patients with seasonalidos-7/17/2009
253NICE CHART SAME AS SVA NVAX HEBmlkr-6/18/2009
252BCRX long and strong. Belive we will hear much news about peramivir and forodesiJoeGMoney-6/12/2009
251Making money is good. The WHO went to phase 6. BCRX is the trusty swine flu stkenhott-6/12/2009
250Hi Kenhott, BCRX on a tear today,over 2 million shares traded at 12 noon cst SP JoeGMoney-6/11/2009
249Baker boys sold a lot here...mopgcw-6/1/2009
248Getting traction now, but there was plenty of time to add at a decent price pretom pope-5/26/2009
247<i>Shionogi Gains as Prepares to Seek Flu Drug Approval (Update1) By Eijitom pope-5/25/2009
246Intramuscular Peramivir Phase 2 Study Results failed for Seasonal Influenza <kenhott-5/8/2009
245exactly...I kept a small slug, but have not seen any fundamental change in theirmopgcw-4/30/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News